

Table 4. Main characteristics of the LAIAs used in Spain^{22,54}.

Active substance	Aripiprazole	Fluphenazine	Olanzapine	Paliperidone palmitate			Risperidone		Zuclopenthixol
Presentation	Abilify Maintena®	Not marketed in Spain	Zypadhera®	Xeplion®	Trevicta®	Byanli®	Risperdal® Consta	Okedi®	Clopixol depot®
Generation	Second generation (atypical)	First generation (typical)	Second generation (atypical)	Second generation (atypical)	Second generation (atypical)	Second generation (atypical)	Second generation (atypical)	Second generation (atypical)	First generation (typical)
Indication approved in SPC	Maintenance of schizophrenia	Treatment and maintenance of schizophrenia and paranoid psychosis	Maintenance of schizophrenia	Maintenance of schizophrenia			Maintenance of schizophrenia	Schizophrenia	Chronic and sub-chronic schizophrenia
Prior stabilisation with oral forms	Yes	Yes	Yes	Not required if prior response to risperidone or paliperidone and mild or moderate symptoms	Not applicable	Not applicable	Yes	Yes. At least 6–14 days if changing from other APs depending on prior response to risperidone	Yes
Prior stabilisation with depot forms	Not applicable	Not applicable	Not applicable	Not applicable	With monthly form	With monthly (100 or 150 mg) or quarterly form (350 or 525 mg)	Not applicable	Not required	Not applicable
Doses available per unit	300 mg and 400 mg	25 mg	210 mg, 300 mg and 405 mg	25 mg, 50 mg, 75 mg, 100 mg and 150 mg	175 mg, 263 mg, 350 mg and 525 mg	700 mg and 1000 mg	25 mg, 37,5 mg and 50 mg	75 mg and 100 mg	200 mg
Administration frequency	Monthly	Every 4–6 weeks	Every 2–4 weeks	Monthly	Quarterly	Six-monthly	Every two weeks	Monthly	Every 2–4 weeks
Maximum recommended dose	400 mg/month	100 mg/4 weeks	300 mg/2 weeks	150 mg/month	525 mg/3 months	1000 mg/six months	50 mg/2 weeks	100 mg/month	400 mg/2 weeks
Location of intramuscular injection	Gluteus or deltoids	Gluteus or deltoids. Also administered subcutaneously	Gluteus	Gluteus or deltoids	Gluteus or deltoids	Gluteus	Gluteus or deltoids	Gluteus or deltoids	Gluteus
Precautions	Monitor QTc	Tardive dyskinesia, neuroleptic malignant syndrome Monitor QTc	Post-injection syndrome Monitor QTc and prolactin	Monitor QTc and prolactin			Monitor QTc and prolactin		Neuroleptic malignant syndrome, dementia patients Monitor QTc
Latency period	Between 14 and 46 days	Between 1 and 4 days		Between 8 and 13 days			Between 3 and 6 weeks	2 hours	Between 3 and 7 days
Storage conditions	Room temperature	Room temperature	Room temperature	Room temperature	Room temperature	Room temperature	Cold (2–8°C)	Room temperature	Room temperature
Cost patient/year*	3785 € - 4101 €	62 € - 234 €	3563 € - 7147 €	1624 € - 3672 €	1839 € - 5117 €	3372 € - 4768 €	3736 € - 5233 €	3386 € - 4021 €	111 € - 429 €

(*) Calculation performed assuming loading dose.